Imperial College London

Professor David Nutt DM, FRCP, FRCPsych, FSB, FMedSci

Faculty of MedicineDepartment of Medicine

The Edmond J Safra Chair in Neuropsychopharmacology
 
 
 
//

Contact

 

d.nutt

 
 
//

Location

 

Burlington Danes BuildingBurlington DanesHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

1248 results found

Badiani A, Berridge KC, Heilig M, Nutt DJ, Robinson TEet al., 2018, Addiction research and theory: a commentary on the Surgeon General's Report on alcohol, drugs, and health, ADDICTION BIOLOGY, Vol: 23, Pages: 3-5, ISSN: 1355-6215

JOURNAL ARTICLE

Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJet al., 2018, Psilocybin with psychological support for treatment-resistant depression: six-month follow-up, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 399-408, ISSN: 0033-3158

JOURNAL ARTICLE

Carrillo F, Sigman M, Fernandez Slezak D, Ashton P, Fitzgerald L, Stroud J, Nutt DJ, Carhart-Harris RLet al., 2018, Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression, JOURNAL OF AFFECTIVE DISORDERS, Vol: 230, Pages: 84-86, ISSN: 0165-0327

JOURNAL ARTICLE

Curran HV, Nutt D, de Wit H, 2018, Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 373-375, ISSN: 0033-3158

JOURNAL ARTICLE

Dukart J, Holiga S, Chatham C, Hawkins P, Forsyth A, McMillan R, Myers J, Lingford-Hughes AR, Nutt DJ, Merlo-Pich E, Risterucci C, Boak L, Umbricht D, Schobel S, Liu T, Mehta MA, Zelaya FO, Williams SC, Brown G, Paulus M, Honey GD, Muthukumaraswamy S, Hipp J, Bertolino A, Sambataro Fet al., 2018, Cerebral blood flow predicts differential neurotransmitter activity, SCIENTIFIC REPORTS, Vol: 8, ISSN: 2045-2322

JOURNAL ARTICLE

Freeman TP, Pope RA, Wall MB, Bisby JA, Luijten M, Hindocha C, Mokrysz C, Lawn W, Moss A, Bloomfield MAP, Morgan CJA, Nutt DJ, Curran HVet al., 2018, Cannabis Dampens the Effects of Music in Brain Regions Sensitive to Reward and Emotion, INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, Vol: 21, Pages: 21-32, ISSN: 1461-1457

JOURNAL ARTICLE

Gabay AS, Carhart-Harris RL, Mazibuko N, Kempton MJ, Morrison PD, Nutt DJ, Mehta MAet al., 2018, Psilocybin and MDMA reduce costly punishment in the Ultimatum Game, SCIENTIFIC REPORTS, Vol: 8, ISSN: 2045-2322

JOURNAL ARTICLE

Heal DJ, Henningfield J, Frenguelli BG, Nutt DJ, Smith SLet al., 2018, Psychedelics - Re-opening the doors of perception., Neuropharmacology

JOURNAL ARTICLE

Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris Ret al., 2018, The hidden therapist: evidence for a central role of music in psychedelic therapy, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 505-519, ISSN: 0033-3158

JOURNAL ARTICLE

Kaelen M, Giribaldi B, Raine J, Evans L, Timmermann C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris Ret al., 2018, The hidden therapist: evidence for a central role of music in psychedelic therapy (vol 235, pg 505, 2018), PSYCHOPHARMACOLOGY, Vol: 235, Pages: 1623-1623, ISSN: 0033-3158

JOURNAL ARTICLE

Morris LS, Baek K, Tait R, Elliott R, Ersche KD, Flechais R, McGonigle J, Murphy A, Nestor LJ, Orban C, Passetti F, Paterson LM, Rabiner I, Reed L, Smith D, Suckling J, Taylor EM, Bullmore ET, Lingford-Hughes AR, Deakin B, Nutt DJ, Sahakian BJ, Robbins TW, Voon Vet al., 2018, Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals, ADDICTION BIOLOGY, Vol: 23, Pages: 425-436, ISSN: 1355-6215

JOURNAL ARTICLE

Rogeberg O, Bergsvik D, Phillips LD, van Amsterdam J, Eastwood N, Henderson G, Lynskey M, Measham F, Ponton R, Rolles S, Schlag AK, Taylor P, Nutt Det al., 2018, A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation, INTERNATIONAL JOURNAL OF DRUG POLICY, Vol: 56, Pages: 144-152, ISSN: 0955-3959

JOURNAL ARTICLE

Rogeberg O, Blomkvist AW, Nutt D, 2018, CANNABIS AND OPIOID OVERDOSES: TIME TO MOVE ON AND EXAMINE POTENTIAL MECHANISMS, ADDICTION, Vol: 113, Pages: 1551-1552, ISSN: 0965-2140

JOURNAL ARTICLE

Roseman L, Nutt DJ, Carhart-Harris RL, 2018, Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression, FRONTIERS IN PHARMACOLOGY, Vol: 8, ISSN: 1663-9812

JOURNAL ARTICLE

Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, Carhart-Harris RLet al., 2018, Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 459-466, ISSN: 0033-3158

JOURNAL ARTICLE

Turton S, Myers JF, Mick I, Colasanti A, Venkataraman A, Durant C, Waldman A, Brailsford A, Parkin MC, Dawe G, Rabiner EA, Gunn RN, Lightman SL, Nutt DJ, Lingford-Hughes Aet al., 2018, Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals., Mol Psychiatry

Addiction has been proposed as a 'reward deficient' state, which is compensated for with substance use. There is growing evidence of dysregulation in the opioid system, which plays a key role in reward, underpinning addiction. Low levels of endogenous opioids are implicated in vulnerability for developing alcohol dependence (AD) and high mu-opioid receptor (MOR) availability in early abstinence is associated with greater craving. This high MOR availability is proposed to be the target of opioid antagonist medication to prevent relapse. However, changes in endogenous opioid tone in AD are poorly characterised and are important to understand as opioid antagonists do not help everyone with AD. We used [11C]carfentanil, a selective MOR agonist positron emission tomography (PET) radioligand, to investigate endogenous opioid tone in AD for the first time. We recruited 13 abstinent male AD and 15 control participants who underwent two [11C]carfentanil PET scans, one before and one 3 h following a 0.5 mg/kg oral dose of dexamphetamine to measure baseline MOR availability and endogenous opioid release. We found significantly blunted dexamphetamine-induced opioid release in 5 out of 10 regions-of-interest including insula, frontal lobe and putamen in AD compared with controls, but no significantly higher MOR availability AD participants compared with HC in any region. This study is comparable to our previous results of blunted dexamphetamine-induced opioid release in gambling disorder, suggesting that this dysregulation in opioid tone is common to both behavioural and substance addictions.

JOURNAL ARTICLE

Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, Husbands SM, Rabiner EIA, Gunn RN, Murphy PS, Parker CA, Nutt DJet al., 2018, Evaluation of 11C-BU99008, a positron emission tomography ligand for the Imidazoline2 binding site in human brain., J Nucl Med

The imidazoline2 binding site (I2BS), are thought to be expressed in glia, and implicated in the regulation of glial fibrillary acidic protein. A PET ligand for this target would be important for the investigation of neurodegenerative and neuroinflammatory diseases. 11C-BU99008 has previously been identified as a putative PET radioligand. Here we present the first in vivo characterisation of this PET radioligand in humans and assess its test-retest reproducibility. Methods 14 healthy male volunteers underwent dynamic PET imaging with 11C-BU99008 and arterial sampling. Six subjects were used to assess test-retest and eight were used in the pharmacological evaluation, undergoing a second, or third heterologous competition scan with the mixed I2BS/α2-adrenoceptor drug, idazoxan (n=8; 20, 40, 60 and 80mg) and the mixed irreversible MAOA/B inhibitor, isocarboxazid (n=4; 50mg), respectively. Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional total distribution volume). All image processing and kinetic analysis was performed in MIAKAT™ (www.miakat.org). Results Brain uptake of 11C-BU99008 was good with reversible kinetics and a heterogeneous distribution consistent with known I2BS expression. Model selection criteria indicated that the 2-tissue-compartment was preferred. VT estimates were high in the striatum (113±20 mL·cm-3), medium in cortex frontal lobe (55±9 mL·cm-3) and low in the cerebellum (47±7 mL·cm-3). Test-retest reliability was found to be reasonable. The uptake was dose-dependently reduced by pre-treatment with idazoxan throughout the brain, with an average block across all regions of ~60% (VT = ~30 mL·cm-3) at the highest dose (80 mg). The ED50 for idazoxan was calculated as 33.1 mg. Uptake was not blocked by pre-treatment with the MAO inhibitor, isocarboxazid. Conclusio

JOURNAL ARTICLE

van den Brink W, Addolorato G, Aubin H-J, Benyamina A, Caputo F, Dematteis M, Gual A, Lesch O-M, Mann K, Maremmani I, Nutt D, Paille F, Perney P, Rehm J, Reynaud M, Simon N, Soederpalm B, Sommer WH, Walter H, Spanagel Ret al., 2018, Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level, ADDICTION BIOLOGY, Vol: 23, Pages: 969-986, ISSN: 1355-6215

JOURNAL ARTICLE

Andersson M, Horder J, Mendez M, Tangen A, Lundberg J, Gee A, Halldin C, Veronese M, Bolte S, Sementa T, Cash D, Turkheimer F, Mick S, Selvaraj S, Nutt D, Lingford-Hughes A, Howes O, Murphy D, Borg Jet al., 2017, A multicenter positron emission tomography study of GABA receptor availability in adults with autism, 30th Congress of the European-College-of-Neuropsychopharmacology (ECNP), Publisher: ELSEVIER SCIENCE BV, Pages: S716-S717, ISSN: 0924-977X

CONFERENCE PAPER

Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Gruenblatt E, Jarema M, Kim Y-K, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Stroehle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer Pet al., 2017, Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition, WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, Vol: 18, Pages: 162-214, ISSN: 1562-2975

JOURNAL ARTICLE

Carhart-Harris RL, Nutt DJ, 2017, Serotonin and brain function: a tale of two receptors, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 31, Pages: 1091-1120, ISSN: 0269-8811

JOURNAL ARTICLE

Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJet al., 2017, Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms, SCIENTIFIC REPORTS, Vol: 7, ISSN: 2045-2322

JOURNAL ARTICLE

Casajuana Kogel C, Mercedes Balcells-Olivero M, Lopez-Pelayo H, Miquel L, Teixido L, Colom J, Nutt DJ, Rehm J, Gual Aet al., 2017, The Standard Joint Unit, DRUG AND ALCOHOL DEPENDENCE, Vol: 176, Pages: 109-116, ISSN: 0376-8716

JOURNAL ARTICLE

Davies B, Brown LA, Cais O, Watson J, Clayton AJ, Chang VT, Biggs D, Preece C, Hernandez-Pliego P, Krohn J, Bhomra A, Twigg SRF, Rimmer A, Kanapin A, Sen A, Zaiwalla Z, McVean G, Foster R, Donnelly P, Taylor JC, Blair E, Nutt D, Aricescu AR, Greger IH, Peirson SN, Flint J, Martin HCet al., 2017, A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability, HUMAN MOLECULAR GENETICS, Vol: 26, Pages: 3869-3882, ISSN: 0964-6906

JOURNAL ARTICLE

Erritzoe D, Colasanti A, Searle G, Lewis Y, Passchier J, Azeem S, Beaver J, Nutt D, Knudsen G, Gunn R, Rabiner Eet al., 2017, Serotonin release measured in the human brain: A PET study with [C-11]Cimbi-36 and d-amphetamine challenge, 28th International Symposium on Cerebral Blood Flow, Metabolism and Function / 13th International Conference on Quantification of Brain Function with PET, Publisher: SAGE PUBLICATIONS INC, Pages: 73-73, ISSN: 0271-678X

CONFERENCE PAPER

Erritzoe D, Nutt DJ, Carhart-Harris R, 2017, Concerns regarding conclusions made about LSD-treatments, HISTORY OF PSYCHIATRY, Vol: 28, Pages: 257-258, ISSN: 0957-154X

JOURNAL ARTICLE

Freeman TP, Pope R, Wall M, Bisby J, Luijten M, Hindocha C, Mokrysz C, Lawn W, Moss A, Bloomfield M, Morgan C, Nutt D, Curran HVet al., 2017, Cannabis increases wanting but not liking of music and dampens its rewarding effects on the brain, European-College-of-Neuropsychopharmacology (ECNP) Workshop for Junior Scientists in Europe, Publisher: ELSEVIER SCIENCE BV, Pages: S92-S93, ISSN: 0924-977X

CONFERENCE PAPER

Law FD, Diaper AM, Melichar JK, Coulton S, Nutt DJ, Myles JSet al., 2017, Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 31, Pages: 1046-1055, ISSN: 0269-8811

JOURNAL ARTICLE

Limbrick-Oldfield EH, Mick I, Cocks RE, McGonigle J, Sharman SP, Goldstone AP, Stokes PRA, Waldman A, Erritzoe D, Bowden-Jones H, Nutt D, Lingford-Hughes A, Clark Let al., 2017, Neural substrates of cue reactivity and craving in gambling disorder, TRANSLATIONAL PSYCHIATRY, Vol: 7, ISSN: 2158-3188

JOURNAL ARTICLE

Maron E, Nutt D, 2017, Biological markers of generalized anxiety disorder, DIALOGUES IN CLINICAL NEUROSCIENCE, Vol: 19, Pages: 147-157, ISSN: 1294-8322

JOURNAL ARTICLE

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00497034&limit=30&person=true